ESMO 2022 | Standard-of-care and future research directions for advanced squamous cell carcinoma

Paolo Ascierto, MD, National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses current treatment options for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), including pembrolizumab and cemiplimab. Dr Ascierto also discusses common co-morbidities that patients with cSCC can experience, as well as research into adjuvant therapies for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.